CN111182903A - 巨环化合物及其用途 - Google Patents

巨环化合物及其用途 Download PDF

Info

Publication number
CN111182903A
CN111182903A CN201880049611.1A CN201880049611A CN111182903A CN 111182903 A CN111182903 A CN 111182903A CN 201880049611 A CN201880049611 A CN 201880049611A CN 111182903 A CN111182903 A CN 111182903A
Authority
CN
China
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880049611.1A
Other languages
English (en)
Chinese (zh)
Inventor
景荣·J·崔
E·W·罗杰斯
J·翁格
J·惠滕
翟大勇
邓维
张欣
黄忠栋
刘靖
张晗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
TP Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65039935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111182903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by TP Therapeutics Inc filed Critical TP Therapeutics Inc
Publication of CN111182903A publication Critical patent/CN111182903A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CN201880049611.1A 2017-07-28 2018-07-26 巨环化合物及其用途 Pending CN111182903A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762538193P 2017-07-28 2017-07-28
US62/538,193 2017-07-28
US201862700990P 2018-07-20 2018-07-20
US62/700,990 2018-07-20
PCT/US2018/043817 WO2019023417A1 (en) 2017-07-28 2018-07-26 MACROCYCLIC COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN111182903A true CN111182903A (zh) 2020-05-19

Family

ID=65039935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049611.1A Pending CN111182903A (zh) 2017-07-28 2018-07-26 巨环化合物及其用途

Country Status (29)

Country Link
US (4) US11286264B2 (https=)
EP (1) EP3658148B1 (https=)
JP (2) JP7224334B2 (https=)
KR (1) KR102645316B1 (https=)
CN (1) CN111182903A (https=)
AU (1) AU2018306328B2 (https=)
BR (1) BR112020001695A2 (https=)
CA (1) CA3069232A1 (https=)
CL (1) CL2020000169A1 (https=)
CO (1) CO2020000633A2 (https=)
DK (1) DK3658148T3 (https=)
ES (1) ES2986593T3 (https=)
FI (1) FI3658148T3 (https=)
HR (1) HRP20241197T1 (https=)
IL (1) IL271964B2 (https=)
LT (1) LT3658148T (https=)
MY (1) MY201925A (https=)
PE (1) PE20200700A1 (https=)
PH (1) PH12020500033A1 (https=)
PL (1) PL3658148T3 (https=)
PT (1) PT3658148T (https=)
RS (1) RS65884B1 (https=)
SA (1) SA520411108B1 (https=)
SG (1) SG11202000356VA (https=)
SI (1) SI3658148T1 (https=)
SM (1) SMT202400343T1 (https=)
TW (1) TWI818917B (https=)
UA (1) UA126158C2 (https=)
WO (1) WO2019023417A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109516999A (zh) * 2017-11-01 2019-03-26 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
CN111620881A (zh) * 2020-07-08 2020-09-04 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113754682A (zh) * 2020-06-04 2021-12-07 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN115397514A (zh) * 2020-03-02 2022-11-25 特普医药公司 大环化合物的治疗用途
CN116063326A (zh) * 2021-11-02 2023-05-05 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
US12129258B2 (en) 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
CA3132632A1 (en) * 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
CN114685532A (zh) * 2020-12-31 2022-07-01 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
WO2022246092A1 (en) * 2021-05-21 2022-11-24 Blossomhill Therapeutics, Inc. Macrocyclic compounds for treating disease
EP4433462A4 (en) * 2021-11-16 2025-07-16 Prodeg Llc USP9X INHIBITORS
US12168640B2 (en) 2021-11-16 2024-12-17 ProDeg, LLC USP9X inhibitors
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1292788A (zh) * 1998-01-12 2001-04-25 葛兰素集团有限公司 作为蛋白酪氨酸激酶抑制剂的二环杂芳族化合物
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
TW201612183A (en) * 2014-09-11 2016-04-01 Tp Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
CN106170289A (zh) * 2014-01-24 2016-11-30 Tp生物医药公司 作为蛋白质激酶的调节剂的二芳基巨环
WO2017004342A1 (en) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195935T1 (de) 1993-03-25 2000-09-15 Upjohn Co Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
DE60120427D1 (de) 2000-08-25 2006-07-20 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
KR20110073500A (ko) 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
KR101226982B1 (ko) 2011-06-10 2013-01-28 가부시키가이샤 멘테크 오염 방지제 조성물
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003802A2 (pt) 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3371190T (pt) * 2015-11-06 2022-07-08 Incyte Corp Compostos heterocíclicos como inibidores de pi3k-gamma
US10689400B2 (en) * 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
ES2896943T3 (es) * 2016-10-28 2022-02-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto de amino pirazolopirimidina usado como inhibidor de receptores con actividad tirosina quinasa de factores neurotróficos
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
CN109956957B (zh) 2017-12-22 2021-11-09 广州白云山医药集团股份有限公司白云山制药总厂 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
US11584759B2 (en) 2018-04-18 2023-02-21 Hitgen Inc. Macrocyclic kinase inhibitor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1292788A (zh) * 1998-01-12 2001-04-25 葛兰素集团有限公司 作为蛋白酪氨酸激酶抑制剂的二环杂芳族化合物
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN106170289A (zh) * 2014-01-24 2016-11-30 Tp生物医药公司 作为蛋白质激酶的调节剂的二芳基巨环
TW201612183A (en) * 2014-09-11 2016-04-01 Tp Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
WO2017004342A1 (en) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STANLEY ET AL.: "Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines", 《SCIENTFIC REPORTS》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109516999A (zh) * 2017-11-01 2019-03-26 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
US12129258B2 (en) 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
CN115397514A (zh) * 2020-03-02 2022-11-25 特普医药公司 大环化合物的治疗用途
CN113754682A (zh) * 2020-06-04 2021-12-07 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
CN113754682B (zh) * 2020-06-04 2023-01-06 赛诺哈勃药业（成都）有限公司 具有大环结构的化合物及其用途
CN111620881A (zh) * 2020-07-08 2020-09-04 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN116829562A (zh) * 2021-02-10 2023-09-29 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN116829562B (zh) * 2021-02-10 2025-04-01 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN116063326A (zh) * 2021-11-02 2023-05-05 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物

Also Published As

Publication number Publication date
EP3658148B1 (en) 2024-07-10
KR102645316B1 (ko) 2024-03-07
US20210214373A1 (en) 2021-07-15
IL271964A (en) 2020-02-27
US12606571B2 (en) 2026-04-21
JP7554300B2 (ja) 2024-09-19
SMT202400343T1 (it) 2024-11-15
DK3658148T3 (da) 2024-10-07
ES2986593T3 (es) 2024-11-12
EP3658148A4 (en) 2021-04-28
FI3658148T3 (fi) 2024-09-20
IL271964B1 (en) 2024-08-01
US20200157119A1 (en) 2020-05-21
CL2020000169A1 (es) 2020-08-14
PH12020500033A1 (en) 2020-09-28
CA3069232A1 (en) 2019-01-31
EP3658148A1 (en) 2020-06-03
LT3658148T (lt) 2024-09-10
US11981684B2 (en) 2024-05-14
BR112020001695A2 (pt) 2020-07-21
PT3658148T (pt) 2024-08-26
MY201925A (en) 2024-03-23
HRP20241197T1 (hr) 2024-11-22
AU2018306328B2 (en) 2023-03-09
RS65884B1 (sr) 2024-09-30
CO2020000633A2 (es) 2020-01-31
PE20200700A1 (es) 2020-06-23
US11155563B2 (en) 2021-10-26
JP2020528907A (ja) 2020-10-01
KR20200034998A (ko) 2020-04-01
TWI818917B (zh) 2023-10-21
SA520411108B1 (ar) 2024-03-03
US11286264B2 (en) 2022-03-29
IL271964B2 (en) 2024-12-01
TW201920198A (zh) 2019-06-01
AU2018306328A1 (en) 2020-01-16
JP7224334B2 (ja) 2023-02-17
US20240391935A1 (en) 2024-11-28
SG11202000356VA (en) 2020-02-27
WO2019023417A1 (en) 2019-01-31
US20220324879A1 (en) 2022-10-13
JP2023065403A (ja) 2023-05-12
SI3658148T1 (sl) 2024-10-30
PL3658148T3 (pl) 2024-10-07
UA126158C2 (uk) 2022-08-25

Similar Documents

Publication Publication Date Title
CN111182903A (zh) 巨环化合物及其用途
KR102599788B1 (ko) 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클
JP6431593B6 (ja) ピリジニルアミノピリミジン誘導体、その製造方法、および用途
CA2799146C (en) Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
JP2020528907A5 (https=)
RU2741000C2 (ru) Производное 1,4-дизамещенного имидазола
TW202134249A (zh) 用於治療疾病的巨環
EA040712B1 (ru) Макроциклические соединения и их использование
OA19985A (en) Macrocyclic compounds and uses thereof.
CN113354630A (zh) 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination